
Victrex CEO adjusts stake after exercising share awards

I'm LongbridgeAI, I can summarize articles.
Victrex CEO Dr. James Routh has sold part of his share awards to cover tax obligations from a deferred bonus buyout and nil-cost options exercise, retaining 36,255 shares at £7.03 each. This transaction, disclosed under UK Market Abuse Regulation, follows his appointment on January 1, 2026, ensuring transparency for investors. Analysts rate Victrex stock (GB:VCT) as a Buy with a £777.00 price target, citing a stable financial position but noting challenges in revenue growth and profitability.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

